Company: Viscera Technologies
Founders: Ryan Quigley & Henry Hollamby
Website: https://www.visceraltd.com/
About Viscera Technologies
Viscera Technologies was founded by Quigley and Hollamby with the aim of preventing chronic illnesses through predictive diagnosis by breaking down barriers to testing. The medtech company’s first project, Helico, was an innovative test for H. Pylori with long-term chronic illness screening capabilities. Viscera secured an announced equity fundraising in July 2019, worth £29k, at a pre-money valuation of £488k.
Viscera Technologies understands the difference that an hour, day, or week can make in the lives of our patients and their loved ones. Time is the most important factor in quality of care, and it is a luxury that many today are robbed of by late diagnosis and delayed treatment. Viscera Technologies is dedicated to fighting disease, not as it presents itself, but before it appears.
As the burden of an ageing population, antibiotic resistance and the rising cost of innovative new therapies is realised, healthcare providers will look to maximise the value of treatment through prevention. Prevention has the potential to redeploy unnecessary costs to improve patient outcomes elsewhere.
Viscera Technologies wants to improve the diagnosis of disease by breaking down barriers to testing. Testing should be simple, low-cost, accurate and convenient. Patients should not have to think twice about being tested, nor should they have to wait for their results.
However, our overarching goal is to prevent chronic illnesses through predictive diagnosis. Diagnosis should not be limited to one’s present health state. When paired with a patient’s past clinical history, a diagnostic result should forecast life-altering health events, before they even have the chance to materialise.
Explaining his motivation for starting Viscera, Quigley said: “We saw that there was a need for a significant improvement in the diagnostic area we are targeting. Specifically, Henry and I both lost relatives to gastro-intestinal complications and we believed that we could improve the diagnostic pathway.” Reflecting on this past year, Quigley told us that “COVID has delayed our development by about 6 months, as all lab time had to be suspended. However, I do believe that COVID has illuminated (especially to the public) the need for efficient diagnostics.”
Currently, Viscera Technologies is developing an innovative diagnostic test for the detection of H.pylori – Helico. Helico promises to be more convenient, accurate and affordable than current solutions. Measurable improvements in each of these three attributes will result in nothing less than a seismic shift in the current testing/treatment paradigm of H.pylori and gastric cancer.
Check out what TechRound can do for your business: SEO, PR, HR Software, Payroll Software, IT, VoIP.
